Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
Gut-Brain Biotech Kallyope Launches
by Lisa M. Jarvis
December 21, 2015
| A version of this story appeared in
Volume 93, Issue 49
Microbiome-focused Kallyope has launched with $44 million in funding from investors including Lux Capital, Polaris Partners, and the Column Group. New York City-based Kallyope will use sequencing, genetics, circuit mapping, neural imaging, and bioinformatics to develop drugs and consumer products that target communication between the brain and the gut. The biotech is founded by three Columbia University scientists—Charles Zuker, Tom Maniatis, and Richard Axel—and will be led by Nancy Thornberry, who previously led Merck & Co.’s diabetes research unit.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter